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Abstract
Chronic inflammation closely associates with obesity, metabolic syndrome, diabetes mellitus, and atherosclerosis. Evidence
indicates that the immunomodulator pentraxin 3 (PTX3) may serve as a biomarker of these cardiometabolic disorders, but
whether PTX3 predicts cardiovascular complications is unknown. We examined the association of plasma PTX3 levels with
recurrent coronary events via a prospective, nested, case-control design in the CARE trial. Among 4159 patients who had a
prior myocardial infarction 3 to 20 months before enrollment and also had total cholesterol levels ,240 mg/dL and LDL
cholesterol levels between 115 and 175 mg/dL, we measured plasma PTX3 levels at baseline by high-sensitivity ELISA in 413
cases with recurrent myocardial infarction or coronary death during a 5-year follow-up period, and in 366 sex- and age-
matched controls. Cases with recurrent coronary events and controls had similar PTX3 levels, and PTX3 did not predict
recurrent coronary events — a finding that contrasts with that of C-reactive protein (CRP) and serum amyloid A (SAA) in this
cohort. We then associated PTX3 levels with metabolic disorders. Low plasma PTX3 levels correlated with high body-mass
index, waist circumference, and triglycerides; and with low HDL cholesterol. Overall, PTX3 levels correlated inversely with the
number of metabolic syndrome components. PTX3 levels also correlated inversely with apoCIII and tissue plasminogen
activator, but did not associate with CRP. Although the study further links low PTX3 levels with various features associated
with metabolic syndrome, the results do not indicate that PTX3 can predict recurrent coronary events among MI survivors.
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Introduction
Pentraxin 3 (PTX3), a member of a superfamily of acute-phase
reactants highly conserved during evolution and characterized by
a cyclic multimeric structure and a ‘‘pentraxin domain’’ in their
carboxy-terminus, figures crucially in innate immunity [1,2]. In
response to inflammatory signals, the liver produces the classic
short pentraxin C-reactive protein (CRP) [3], which strongly
associates with cardiometabolic disorders such as obesity, meta-
bolic syndrome, diabetes mellitus, and atherosclerosis [4]. In
contrast, a variety of immune and resident cells involved in
cardiometabolic disorders — including macrophages, dendritic
cells, fibroblasts, smooth muscle cells, endothelial cells, and
adipocytes — secrete the long pentraxin PTX3 [1]. While some
previous clinical and preclinical studies report pro-inflammatory
properties of PTX3, others show its anti-inflammatory actions [5–
17]. Thus, the role of PTX3 in the pathogenesis of obesity,
metabolic syndrome, diabetes mellitus, and atherosclerosis re-
mains uncertain.
Evidence suggests that PTX3 serves as a biomarker of
inflammatory diseases, including atherosclerosis and metabolic
disorders [18,19]. Yamasaki et al. reported that PTX3 levels were
inversely associated with the features of metabolic syndrome in a
healthy population [20]. But the intriguing possibility that PTX3 is
a risk predictor of future cardiovascular complications (e.g., acute
myocardial infarction) remains obscure. Other unresolved issues
include which metabolic components mainly associate with plasma
PTX3 levels; whether plasma PTX3 levels correlate with insulin
resistance or diabetes mellitus; and the association of PTX3 with
other inflammatory markers. The present study examined plasma
PTX3 levels in participants of the Cholesterol and Recurrent
Events (CARE) trial (UMIN-CTR; UMIN000012519) to test the
hypothesis that plasma PTX3 levels predict future coronary events




We conducted a prospective, nested, case-control study within
the CARE trial (See methods S1). This randomized, double-
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blind, placebo-controlled trial included 4159 patients with a prior
myocardial infarction (MI) that occurred 3 to 20 month before
enrollment. The subjects had low-density lipoprotein (LDL)
cholesterol levels (total cholesterol levels ,240 mg/dL and LDL
cholesterol levels between 115 and 175 mg/dL). Patients under-
went random allocation to 40 mg pravastatin or placebo for a
median of 5 years [21]. The institutional review board at each
participating clinical center approved the study, and individuals
gave written informed consent [22]. During the trial, 486 patients
experienced the primary endpoint of coronary death or MI.
Sufficient plasma for analysis was available from 413 of these
cases. We randomly selected control subjects from patients who
did not have a primary endpoint, matched to the cases by sex and
decade of age. Measurement of PTX3 levels of these blood
samples from the CARE trial and this analysis were approved by
the committee for the Protection Against Research Risks of
Brigham and Women’s Hospital, Harvard medical school.
Blood collection and laboratory measurements
A fasting blood sample was taken from each patient at baseline.
Serial measurements of PTX3 were performed using a high-
sensitivity ELISA (Perseus Proteomics Inc., Tokyo, Japan). Plasma
lipid profiles, fasting blood glucose and insulin, serum creatinine
levels, and tissue plasminogen activator (tPA) were measured as
previously described. High-sensitivity assays for CRP and serum
amyloid A (SAA) were performed [23].
Definition of metabolic syndrome
We defined metabolic syndrome using the modified 2005
National Cholesterol Education Program Adult Treatment Panel
III (NCEP-ATP III) definition as 3 or more of the following: waist
Table 1. Baseline characteristics of the 366 controls in the CARE populations by quartiles of PTX3.
Quartile of PTX3
Q1 Q2 Q3 Q4
Median PTX3 2.1 2.9 4.1 6.1
Range ,2.6 2.6–3.4 3.5–5.0 .5.0 p-trend
Age (years) 56 59 60 62 ,0.001
Male (%) 85 92 89 81 0.18
Current smoker (%) 12 8 8 13 0.76
History of diabetes (%) 4 12 7 13 0.15
History of hypertension (%) 41 34 40 46 0.29
Family history of CVD (%) 44 33 35 53 0.06
Body-mass index (kg/m2) 27.6 28.8 27.6 25.6 ,0.001
Waist circumference (in) 38 40 38 36 ,0.001
Metabolic syndrome (%) 46 48 46 32 0.03
Number of metabolic syndrome components 2.3 2.3 2.2 1.8 0.01
Total cholesterol (mmol/L) 190 183 193 193 0.20
HDL cholesterol (mmol/L) 40 40 42 45 ,0.001
LDL cholesterol (mmol/L) 118 114 120 121 0.20
Triglycerides (mmol/L) 163 147 158 134 0.01
High-sensitivity CRP (mg/L) 3.8 4.4 4.9 5.3 0.13
Serum amyloid A (mg/L) 3.5 7.1 5.9 10.9 0.04
Apo CIII (mg/dL) 11.6 11.4 11.7 10.6 0.05
tPA, median (IQR) (ng/mL) 12.5 10.7 10.1 9.3 0.03
Fasting plasma glucose (mmol/L) 98 107 103 98 0.35
Fasting insulin (pmol/L) 8.6 10.8 8.8 10.9 0.65
HOMA-IR 2.2 2.9 2.4 2.7 0.78
Serum creatinine 1.14 1.12 1.07 1.13 0.67
MDRD-GFR 69.7 73.4 75.9 70.5 0.96
Medication use (%)
Anti-coagulant 3 1 3 7 0.08
Anti-arrhythmic 50 54 43 42 0.17
Aspirin 73 84 87 75 0.94
Diabetic medications 3 7 4 6 0.52
Cholesterol medication 33 45 37 41 0.62
Hypertension medication 26 27 23 29 0.79
IQR = interquartile range. MDRD-GFR = Modification of Diet in Renal Disease-Glomerular Filtration Rate.
doi:10.1371/journal.pone.0094073.t001
PTX3 Levels Do Not Predict Coronary Events
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circumference $40 inches in men or $35 inches in women;
systolic blood pressure $130 or diastolic blood pressure $85 mm
Hg or antihypertensive treatment in a patients with history of
hypertension; triglycerides $150 mg/dL; HDL cholesterol #
40 mg/dL in men or 50 mg/dL in women; and glucose $
100 mg/dL or history of diabetes mellitus or use of anti-diabetic
medication [24]. In addition, we categorized body-mass index
(BMI) according to the World Health Organization (WHO)
criteria: BMI,25 kg/m2 = healthy weight, BMI 25–29.9 kg/m2
= overweight, and BMI $30 kg/m2 = obese.
Statistical analysis
For analysis comparing cases and controls, continuous variables
are shown as means (standard deviation) or medians (inter quartile
range), and the unpaired t test or the Wilcoxon unpaired rank sum
test compared cases and controls. Proportions were compared
using the x2 test. Spearman correlations assessed the relation
between continuous variables. We used unconditional logistic
regression to calculate the odds ratio and 95% confidence interval
(CI) of coronary heart disease (CHD). Tests for linear trend, for
both the linear regression and logistic regression models, used the
Table 2. Characteristics of cases and controls within the CARE trial.
Controls (n =336) Cases (n=413) P-value
Age (years) 60 (10) 60 (10) 0.73
Pentraxin, mean (min, max) (ng/ml) 3.9 (0.8, 12.5) 4.1 (0.5, 16.3)
Pentraxin, median (IQR) (ng/ml) 3.5 (2.6, 5.1) 3.8 (2.7, 5.0) 0.12
Male (%) 87 87 0.83
Current smoker (%) 10 23 ,0.001
History of diabetes (%) 9 22 ,0.001
History of hypertension (%) 40 48 0.03
Family history of CVD (%) 41 38 0.29
Body-mass index (kg/m2) 27.4 (4.2) 28.3 (4.9) 0.01
Waist circumference (in) 38.1 (4.5) 39.0 (5.2) 0.01
Metabolic syndrome (%) 43% 56% ,0.001
Number of metabolic syndrome components 2.1 (1.3) 2.4 (1.3) ,0.001
Total cholesterol (mmol/L) 4.91 (0.80) 5.04 (0.80) 0.01
HDL cholesterol (mmol/L) 1.09 (0.25) 1.01 (0.25) 0.001
LDL cholesterol (mmol/L) 3.05 (0.70) 3.18 (0.72) 0.01
Triglycerides, median (IQR) (mmol/L) 1.52 (1.15, 2.07) 1.70 (1.25, 2.21) 0.003
High-sensitivity CRP (mg/L) 4.6 (7.0) 5.5 (7.3) 0.06
Serum amyloid A (mg/L) 6.9 (21.4) 7.2 (16.8) 0.79
Apo CIII (mg/dL) 11.3 (3.3) 12.1 (3.6) 0.003
tPA, median (IQR) (ng/mL) 9.6 (7.2, 12.0) 10.1 (7.5, 13.2) 0.10
Fasting plasma glucose (mmol/L) 5.66 (1.34) 6.16 (2.10) ,0.001
Fasting insulin, median (IQR) (pmol/L) 42.6 (31.2, 61.2) 42.6 (30.6, 55.8) 0.12
Serum creatinine 1.11 (0.2) 1.15 (0.2) 0.01
MDRD-GFR 72.4 (15) 70.2 (15) 0.04
Treatment group (%) 48 42 0.1
Medication use (%)
Anti-arrhythmic 47 59 0.001
Anti-coagulants 4 7 0.04
Aspirin 80 78 0.59
Lipid-lowering drugs 9 13 0.05
Beta-blockers 39 46 0.04
Calcium channel blockers 36 40 0.21
Insulin 1 4 0.01
Oral hypoglycemic drugs 4 14 ,0.001
All values are means (standard deviations) unless otherwise noted.
IQR = interquartile range. MDRD-GFR = Modification of Diet in Renal Disease-Glomerular Filtration Rate. Continuous variables are shown as means (standard deviation)
or medians (inter quartile range).
doi:10.1371/journal.pone.0094073.t002
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median score variables. A probability value of 0.05 was considered
statistically significant.
Results
Plasma PTX3 levels associate with features typical of
metabolic syndrome, but do not predict recurrent
coronary events
Table 1 presents the mean values for selected characteristics
among the controls, according to quartiles of plasma PTX3
concentration. Participants with higher PTX3 concentration
generally had lower prevalence of metabolic syndrome, as well
as favorable levels of various components associated with
metabolic syndrome — including lower BMI, waist circumference,
triglycerides, apoCIII and tPA, and higher levels of high-density
lipoprotein (HDL) cholesterol. Participants with higher PTX3
concentrations also had higher levels of the inflammatory marker
SAA, but not of CRP. High PTX3 concentration was not
associated with fasting glucose, insulin or the HOMA index.
Table 3. Odds ratio of CHD (nonfatal MI and fatal CHD) by quartiles of pentraxin 3 concentration.
Quartiles of pentraxin
Q1 Q2 Q3 Q4 Trend
Range 0.83–2.60 2.60–3.48 3.48–5.04 5.05–12.5
Median 2.14 2.92 4.15 6.08
Cases 87 90 136 100
Controls 91 92 91 92
Age and sex adjusted 1.0 (ref) 1.03 (0.68–1.56) 1.59 (1.07–2.38) 1.17 (0.77–1.78) 0.29
Multivariate adjusted 1 1.0 (ref) 0.93 (0.60–1.44) 1.48 (0.97–2.25) 1.03 (0.66–1.59) 0.60
Multivariate adjusted 2 1.0 (ref) 0.96 (0.62–1.51) 1.55 (1.00–2.42) 1.08 (0.68–1.72) 0.48
Multivariate 1: adjusted for age, sex, smoking, left ventricular ejection fraction, and history of diabetes.
Multivariate 2: adjusted for age, sex, smoking, left ventricular ejection fraction, history of diabetes, CRP, SAA, metabolic risk factors (systolic blood pressure, diastolic
blood pressure, glucose, HDL, triglycerides, waist circumference), glomerular filtration rate, and medication use (diabetic medication, hypertension medication,
cholesterol medication, anti-arrhythmics, and anti-coagulants).
doi:10.1371/journal.pone.0094073.t003
Figure 1. PTX3 levels associate adversely with metabolic syndrome components. Mean values of selected characteristics (BMI, waist
circumference, triglyceride, and HDL cholesterol) by quartile of PTX3. Mean values were estimated from linear regression models, adjusted for age.
doi:10.1371/journal.pone.0094073.g001
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Compared with controls, cases had higher BMI and waist
circumference, and more smoked cigarettes currently, had
diabetes and hypertension, and took cardiovascular medications
(Table 2). The cases had higher levels of total cholesterol, LDL
cholesterol, triglycerides, and plasma glucose, and lower HDL
cholesterol levels than the controls. No significant difference in
plasma PTX3 levels occurred between the cases and controls.
PTX3 did not predict CHD risk (nonfatal MI and fatal CHD),
even after adjustment for metabolic syndrome components, other
coronary risk factors, and medication use (Table 3).
PTX3 levels associate with components of metabolic
syndrome
Individuals with metabolic syndrome had lower PTX3 levels
(mean = 3.89 ng/mL, SE = 0.10, n= 397) than those without
metabolic syndrome (4.22 ng/mL, SE = 0.10, P=0.02, n= 382),
after adjustment for age, sex, and smoking. Additionally, plasma
PTX3 levels correlated inversely with variables associated with
metabolic syndrome (Figure 1), including BMI, waist circumfer-
ence, and triglycerides, while positively correlating with HDL
cholesterol after adjustment for age. Plasma PTX3 remained
statistically significant in association with BMI (P trend,0.001) and
waist circumference (P trend ,0.001) even after adjustment for age,
sex, smoking, history of hypertension, triglycerides, HDL choles-
terol, and insulin.
Lower PTX3 levels in obese, non-diabetic individuals
Obese patients had lower levels of adjusted mean PTX3 (mean
= 3.77 ng/mL, SE= 0.13) than did non-obese patients (mean
= 4.15 ng/mL, SE= 0.08, Figure 2A). Conversely, patients with
diabetes (mean =4.53 ng/mL, SE =0.11) had higher adjusted
mean PTX3 concentrations than did controls without diabetes
(mean = 3.96 ng/mL, SE = 0.07, Figure 2A). To probe further
the association of PTX3 and obesity, we stratified the control
subjects by diabetic status. Compared to patients with a healthy
weight (BMI ,25), both overweight patients (25# BMI ,30) and
obese patients (BMI $30) had lower mean plasma PTX3 levels
among those without diabetes (n = 655), after adjustment for
confounders (Figure 2B). Patients with diabetes (n = 124) had no
significant difference in mean plasma PTX3 levels in different
categories of BMI (Figure 2B). Of the 124 patients with diabetes
mellitus, 88 patients (71%) took medications for this condition.
PTX3 levels associate inversely with components of
metabolic syndrome in all individuals and non-diabetic
individuals
We further explored the association between PTX3, metabolic
syndrome, and diabetes mellitus. PTX3 associated inversely with
the total number of metabolic syndrome components in all
individuals (n = 779) after adjustment for age, sex, and smoking
(Figure 2C). Non-diabetic patients (n = 655) showed a stronger
inverse association between PTX3 and total number of metabolic
syndrome components (Figure 2C).
PTX3 levels do not correlate with CRP levels
PTX3 levels did not correlate with levels of the short pentraxin
CRP (Figure 3A), and very weakly and positively correlated with
another inflammatory marker, SAA (Figure 3B). CRP and SAA
correlated with each other strongly and positively (Figure 3C).
After exclusion of participants with CRP above 10 mg/L
(n= 687), PTX3 showed no significant correlations with CRP or
SAA (Figure 3D and 3E), whereas CRP and SAA correlated
positively with each other (Figure 3F), suggesting that different
mechanisms regulate levels of the long and short pentraxin in these
MI survivors.
Discussion
This analysis from the CARE trial tested the hypothesis that
plasma levels of the immunomodulator PTX3 predict risk of acute
complications of coronary atherosclerosis in a population of MI
Figure 2. PTX3 associates negatively with obesity and meta-
bolic syndrome in non-diabetic subject. PTX3 associates nega-
tively with obesity but positively with diabetes mellitus (A). Mean
plasma PTX3 levels among 779 individuals, comparing non-obese (BMI
,30) and obese individuals (BMI $30) (left), or non-diabetic and
diabetic control individuals (right). Mean values were estimated from
linear regression models, adjusted for age, sex, smoking status,
triglycerides, HDL cholesterol, and hypertension. Models for diabetes
also adjusted for BMI. PTX3 negatively associates with obesity among
non-diabetic individuals (B). Mean values of plasma PTX3 levels by BMI
category in non-diabetic (left) and diabetic individuals (right) estimated
from linear regression models. Mean values adjusted for age, sex,
smoking status, triglycerides, HDL cholesterol, and hypertension. PTX3
associates negatively with the number of metabolic syndrome
components (C). Mean values of plasma PTX3 levels according to
presence of 0, 1, 2, 3, and 4 or more components of metabolic
syndrome in all individuals (left) and non-diabetic individuals (right).
Mean values estimated from linear regression models, adjusted for age,
sex, and smoking status.
doi:10.1371/journal.pone.0094073.g002
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survivors and also associated with cardiometabolic disorders.
Although our results demonstrate that plasma PTX3 levels
associate inversely with components of metabolic syndrome, the
study does not support a relation between this pentraxin and
recurrent CHD risk, unlike other pentraxin family members such
as CRP.
Several clinical studies have reported elevated plasma PTX3
levels in patients following acute MI or unstable angina [5–7]. In
patients with heart failure, elevated plasma PTX3 levels associated
independently with cardiac events but did not specifically correlate
with coronary events [8,14]. Other clinical studies indicated that
PTX3 levels associate with cardiovascular disease and all-cause
death among apparently healthy older individuals and patients
with CHD [11,16]. These studies led to our intriguing hypothesis
that PTX3 serves as a predictor of cardiovascular risk. In the
population studied here with prior history of MI, however, plasma
PTX3 levels did not predict subsequent events. The difference in
the study population (e.g., primary vs. secondary prevention) may
pertain to this discrepancy, although other risk factors including
CRP have similar associations with cardiovascular disease in
primary and secondary prevention. The pro-inflammatory or anti-
inflammatory role of PTX3 may also depend on the relative
contribution of producing cell types, the disease context, and/or
the stage of disease. Although PTX3 may associate with coronary
events in other populations, the present study does not support its
role as a risk predictor.
The causal role of PTX3 in the pathogenesis of atherosclerosis
remains obscure. Macrophages, endothelial cells, smooth muscle
cells, and neutrophils abundantly express PTX3 in human
atherosclerotic lesions [25,26]. In vitro studies demonstrated that
pro-inflammatory stimuli (e.g., LPS, TNF-a, IL-1b, and oxidized
LDL) [27–30] and anti-inflammatory stimuli (e.g., IL-10 and
HDL) [31,32] enhance PTX3 production. In rats, forced
expression of PTX3 reduces neointima formation after balloon
injury, indicating that this long pentraxin can limit intimal
hyperplasia [9]. PTX3-deficient mice with acute MI showed
increased myocardial damage, and exogenous PTX3 expression
rescued this phenotype, suggesting a cardioprotective function of
PTX3 [10]. Furthermore, PTX3 deficiency in mice worsened
atherosclerotic lesions and inflammatory profiles [12]. Further
investigations may elucidate the specific role of PTX3 in various
contexts of cardiovascular disease.
Obesity and metabolic syndrome represent chronic inflamma-
tory states [33–35]. Whereas plasma levels of the short pentraxin
CRP are higher in obese individuals and those with metabolic
syndrome [36], evidence linking PTX3 with obesity and metabolic
syndrome remains scant. The present study using MI survivors,
and another clinical study in a healthy Japanese population, found
that PTX3 is inversely correlated with obesity and metabolic
Figure 3. Lack of association between PTX3 and short pentraxin. Spearman correlations revealed no association between plasma levels of
the long pentraxin PTX3 and the short pentraxin CRP (A). Plasma PTX3 levels positively correlated with plasma SAA levels (B), and plasma CRP and
SAA levels correlated strongly with each other (C). After exclusion of participants with high CRP levels (.10 mg/L), PTX3 showed no significant
correlations with CRP and SAA (D and E), whereas CRP and SAA correlated positively with each other (F).
doi:10.1371/journal.pone.0094073.g003
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syndrome [20]. In addition, patients with end-stage renal disease
show inverse correlations of plasma PTX3 levels with BMI and
waist circumference [15]. Another study reported decreased PTX3
mRNA expression in mature adipocytes derived from human
adipose tissue, compared to that in preadipocytes [37]. These
divergent results for CRP and PTX3 results may reflect different
sources and biologic roles of the short and long pentraxins.
Previous studies, including our own, have reported that various
cell types associated with atherosclerosis and metabolic syndrome
produce PTX3 in response to inflammatory signals, while the liver
elaborates most circulating CRP [1,27,29,30,38,39]. HDL induces
PTX3 mRNA expression and protein release in human endothe-
lial cells through activation of the PI3K/Akt pathway [32], which
may contribute to low plasma PTX3 levels in individuals with
metabolic syndrome who have low HDL levels. PTX3 correlated
inversely with triglycerides and with apoCIII, which interferes with
clearance of triglyceride-rich lipoproteins from plasma [40]. We
recently established that apoCIII induces cell activation and
inflammation in vitro and in vivo [41]. Interaction between
apoCIII and PTX3 requires further study. While several previous
reports demonstrated significant positive associations between
PTX3 and CRP [42], others showed no significant correlation
[5,6]. PTX3 did not correlate significantly with CRP in our
population. The distinct behaviors of PTX3 compared with those
of CRP also suggest that long and short pentraxins have different
relationships with the pathogenesis of obesity and metabolic
syndrome.
In this study population, individuals with diabetes had higher
plasma PTX3 levels than non-diabetic individuals although PTX3
did not correlate with fasting glucose, insulin or the HOMA-IR.
More than 70% of diabetic patients took medications for diabetes
mellitus, suggesting that these treatments affected the association
between plasma PTX3 levels and diabetes mellitus in our study
population. To clarify the effect of obesity on plasma PTX3 levels
independent of diabetes mellitus, we divided study participants
into diabetic and non-diabetic groups. Among individuals without
diabetes, obese individuals had lower plasma PTX3 levels than
lean individuals. Moreover, non-diabetic individuals showed a
significant inverse correlation between PTX3 and the number of
metabolic syndrome components.
This study has a few limitations. We did not measure PTX3
levels in patients who received pravastatin. The present study
tested the specific hypothesis that plasma PTX3 levels predict risk
of recurrent cardiovascular events in MI survivors. We thus
measured PTX3 levels only at the baseline in case and control
subjects. Our results indicated that PTX3 levels did not associate
with future recurrent events in the CARE study cohort. As the
present study did not to identify PTX3 as a biomarker of
cardiovascular risk, we did not measure PTX3 levels during the
follow-up period in control and pravastatin-treated subjects.
Several studies have linked higher PTX3 levels with heart failure
[8,14]. Because CARE did not adjudicate heart failure endpoints,
we did not examine the association between PTX3 levels and
heart failure.
The present study indicates that PTX3 does not predict future
cardiac events, unlike CRP, although it associates with reduced
levels of cardiometabolic risk factors. Various features associated
with metabolic syndrome correlate negatively with PTX3 levels
but positively with CRP. The underlying mechanisms may involve
complex processes regulating PTX3 production in various cell
types activated in the pro-inflammatory microenvironment of
patients with cardiometabolic syndrome. Although the present
study offers clinical evidence that further links PTX3 with
metabolic syndrome, understanding the biology of this immuno-
modulator in cardiometabolic disorders requires additional
multidisciplinary investigations.
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